News

The work is being coordinated by AGTC under an agreement with researchers at Oregon Health & Science University Casey Eye Institute, David Wilson and The University of Florida,

AP-1531 is a potent and selective EP4 receptor antagonist that targets PGE2-EP4 binding which may treat migraines. In earlier studies, AP-1531 has demonstrated positive results in several disease

MWI distributes animal health products including feed additives, pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. to veterinarians across the US and UK.

During the trial, Olesoxime is dosed at 330mg oral capsules once a day and riluzole is dosed in both arms at 50mg twice a day. In total, the

The funding was granted by CTI Life Sciences Fund (CTI), Advanced Biotechnologies Venture Fund (ABVF) and by several existing private shareholders. Zymeworks president and CEO said the investment

The FBP vaccine is a composition of E39 peptide combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). RXi Pharma president and CEO Mark Ahn said

The results from two previous Phase I trial demonstrated that the drug was safe and well tolerated when administered in healthy volunteers. NI-0801 is a fully human monoclonal

CF-301, produced by fermentation at concentrations exceeding 5g/l, is soluble, stable and potent. The Lysins possess a therapeutic window that occurs virtually instantly while the Monoclonal Antibodies remain

As per the previous agreement, both the firms collaborated for the commercialization of Sinclair’s dermatology brands in eleven Asia Pacific countries. Under an agreement, the companies have launched